Therapy in non-hypertensive and hypertensive patients, stratified by age groups
| . | Non-hypertensive (n = 836) . | Hypertensive (n = 1450) . | P-value . | ||||
|---|---|---|---|---|---|---|---|
| <45 years (n = 125) . | 45–65 years (n = 382) . | >65 years (n = 329) . | <45 years (n = 45) . | 45–65 years (n = 552) . | >65 years (n = 853) . | ||
| Therapy before admission | |||||||
| Aspirin | 10 (8.0) | 37 (9.7) | 46 (14.0) | 7 (15.6) | 144 (26.1) | 287 (33.7) | <0.001 |
| Clopidogrel | 1 (0.8) | 11 (2.9) | 4 (1.2) | 2 (4.5) | 29 (5.3) | 37 (4.3) | 0.02 |
| Beta-blockers | 5 (4.0) | 45 (11.8) | 46 (14.0) | 11 (24.4) | 172 (31.2) | 299 (35.1) | <0.001 |
| ACE inhibitors | 2 (1.6) | 18 (4.7) | 45 (13.7) | 8 (17.8) | 201 (36.4) | 387 (45.4) | <0.001 |
| ARBs | 2 (1.6) | 2 (0.5) | 3 (0.9) | 3 (6.7) | 16 (2.9) | 37 (4.3) | <0.001 |
| CCB | 3 (2.4) | 11 (2.9) | 11 (3.3) | 1 (2.2) | 48 (8.7) | 132 (14.5) | <0.001 |
| Statins | 7 (5.6) | 35 (9.2) | 31 (9.4) | 9 (20.0) | 118 (21.49) | 189 (22.2) | <0.001 |
| Therapy at index event | |||||||
| Fibrinolysis | 51 (40.8) | 153 (40.0) | 75 (22.8) | 12 (26.7) | 177 (32.0) | 119 (14.0) | <0.001 |
| Primary or urgent PCI | 20 (16.0) | 36 (9.4) | 14 (4.3) | 8 (17.8) | 59 (10.7) | 56 (6.6) | <0.001 |
| In-hospital therapy | |||||||
| Aspirin and/or clopidogrel | 122 (97.6) | 376 (98.4) | 313 (95.1) | 45 (100) | 540 (97.8) | 827 (96.9) | 0.18 |
| Heparins | 124 (99.2) | 374 (97.9) | 309 (93.9) | 44 (97.8) | 542 (98.2) | 811 (95.1) | 0.001 |
| Beta- blockers | 117 (93.6) | 332 (86.9) | 239 (72.6) | 42 (93.3) | 513 (92.9) | 671 (78.7) | <0.001 |
| ACE inhibitors or ARBs | 109 (87.2) | 306 (80.1) | 231 (70.2) | 42 (93.3) | 501 (90.8) | 727 (85.2) | <0.001 |
| CCBs | 12 (9.6) | 9 (2.4) | 12 (3.7) | 3 (6.7) | 40 (7.3) | 77 (9.0) | 0.001 |
| Statins | 117 (93.6) | 332 (86.9) | 259 (78.7) | 41 (91.1) | 522 (94.6) | 763 (89.5) | <0.001 |
| Therapy at discharge | |||||||
| Aspirin and/or clopidogrel | 123 (98.4) | 338 (88.5) | 255 (77.5) | 40 (88.9) | 509 (98.2) | 688 (80.7) | <0.001 |
| ACE inhibitors or ARBs | 102 (81.6) | 289 (875.7) | 219 (66.6) | 40 (88.9) | 471 (85.3) | 653 (76.6) | <0.001 |
| Beta-blockers | 114 (91.2) | 318 (83.3) | 223 (67.8) | 39 (86.7) | 483 (87.5) | 613 (71.79 | <0.001 |
| CCB | 11 (8.8) | 14 (3.7) | 18 (5.5) | 3 (6.7) | 41 (7.4) | 82 (9.69 | 0.01 |
| Statins | 114 (91.2) | 314 (82.2) | 232 (70.5) | 39 (86.7) | 493 (89.3) | 662 (77.6) | <0.001 |
| Diuretics | 6 (4.8) | 41 (10.7) | 76 (23.1) | 5 (11.19 | 141 (25.5) | 285 (33.4) | <0.001 |
| . | Non-hypertensive (n = 836) . | Hypertensive (n = 1450) . | P-value . | ||||
|---|---|---|---|---|---|---|---|
| <45 years (n = 125) . | 45–65 years (n = 382) . | >65 years (n = 329) . | <45 years (n = 45) . | 45–65 years (n = 552) . | >65 years (n = 853) . | ||
| Therapy before admission | |||||||
| Aspirin | 10 (8.0) | 37 (9.7) | 46 (14.0) | 7 (15.6) | 144 (26.1) | 287 (33.7) | <0.001 |
| Clopidogrel | 1 (0.8) | 11 (2.9) | 4 (1.2) | 2 (4.5) | 29 (5.3) | 37 (4.3) | 0.02 |
| Beta-blockers | 5 (4.0) | 45 (11.8) | 46 (14.0) | 11 (24.4) | 172 (31.2) | 299 (35.1) | <0.001 |
| ACE inhibitors | 2 (1.6) | 18 (4.7) | 45 (13.7) | 8 (17.8) | 201 (36.4) | 387 (45.4) | <0.001 |
| ARBs | 2 (1.6) | 2 (0.5) | 3 (0.9) | 3 (6.7) | 16 (2.9) | 37 (4.3) | <0.001 |
| CCB | 3 (2.4) | 11 (2.9) | 11 (3.3) | 1 (2.2) | 48 (8.7) | 132 (14.5) | <0.001 |
| Statins | 7 (5.6) | 35 (9.2) | 31 (9.4) | 9 (20.0) | 118 (21.49) | 189 (22.2) | <0.001 |
| Therapy at index event | |||||||
| Fibrinolysis | 51 (40.8) | 153 (40.0) | 75 (22.8) | 12 (26.7) | 177 (32.0) | 119 (14.0) | <0.001 |
| Primary or urgent PCI | 20 (16.0) | 36 (9.4) | 14 (4.3) | 8 (17.8) | 59 (10.7) | 56 (6.6) | <0.001 |
| In-hospital therapy | |||||||
| Aspirin and/or clopidogrel | 122 (97.6) | 376 (98.4) | 313 (95.1) | 45 (100) | 540 (97.8) | 827 (96.9) | 0.18 |
| Heparins | 124 (99.2) | 374 (97.9) | 309 (93.9) | 44 (97.8) | 542 (98.2) | 811 (95.1) | 0.001 |
| Beta- blockers | 117 (93.6) | 332 (86.9) | 239 (72.6) | 42 (93.3) | 513 (92.9) | 671 (78.7) | <0.001 |
| ACE inhibitors or ARBs | 109 (87.2) | 306 (80.1) | 231 (70.2) | 42 (93.3) | 501 (90.8) | 727 (85.2) | <0.001 |
| CCBs | 12 (9.6) | 9 (2.4) | 12 (3.7) | 3 (6.7) | 40 (7.3) | 77 (9.0) | 0.001 |
| Statins | 117 (93.6) | 332 (86.9) | 259 (78.7) | 41 (91.1) | 522 (94.6) | 763 (89.5) | <0.001 |
| Therapy at discharge | |||||||
| Aspirin and/or clopidogrel | 123 (98.4) | 338 (88.5) | 255 (77.5) | 40 (88.9) | 509 (98.2) | 688 (80.7) | <0.001 |
| ACE inhibitors or ARBs | 102 (81.6) | 289 (875.7) | 219 (66.6) | 40 (88.9) | 471 (85.3) | 653 (76.6) | <0.001 |
| Beta-blockers | 114 (91.2) | 318 (83.3) | 223 (67.8) | 39 (86.7) | 483 (87.5) | 613 (71.79 | <0.001 |
| CCB | 11 (8.8) | 14 (3.7) | 18 (5.5) | 3 (6.7) | 41 (7.4) | 82 (9.69 | 0.01 |
| Statins | 114 (91.2) | 314 (82.2) | 232 (70.5) | 39 (86.7) | 493 (89.3) | 662 (77.6) | <0.001 |
| Diuretics | 6 (4.8) | 41 (10.7) | 76 (23.1) | 5 (11.19 | 141 (25.5) | 285 (33.4) | <0.001 |
Values are expressed as numbers, n (%) or mean ± SD.
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptors blockers; CCBs, calcium-channel blockers.
Therapy in non-hypertensive and hypertensive patients, stratified by age groups
| . | Non-hypertensive (n = 836) . | Hypertensive (n = 1450) . | P-value . | ||||
|---|---|---|---|---|---|---|---|
| <45 years (n = 125) . | 45–65 years (n = 382) . | >65 years (n = 329) . | <45 years (n = 45) . | 45–65 years (n = 552) . | >65 years (n = 853) . | ||
| Therapy before admission | |||||||
| Aspirin | 10 (8.0) | 37 (9.7) | 46 (14.0) | 7 (15.6) | 144 (26.1) | 287 (33.7) | <0.001 |
| Clopidogrel | 1 (0.8) | 11 (2.9) | 4 (1.2) | 2 (4.5) | 29 (5.3) | 37 (4.3) | 0.02 |
| Beta-blockers | 5 (4.0) | 45 (11.8) | 46 (14.0) | 11 (24.4) | 172 (31.2) | 299 (35.1) | <0.001 |
| ACE inhibitors | 2 (1.6) | 18 (4.7) | 45 (13.7) | 8 (17.8) | 201 (36.4) | 387 (45.4) | <0.001 |
| ARBs | 2 (1.6) | 2 (0.5) | 3 (0.9) | 3 (6.7) | 16 (2.9) | 37 (4.3) | <0.001 |
| CCB | 3 (2.4) | 11 (2.9) | 11 (3.3) | 1 (2.2) | 48 (8.7) | 132 (14.5) | <0.001 |
| Statins | 7 (5.6) | 35 (9.2) | 31 (9.4) | 9 (20.0) | 118 (21.49) | 189 (22.2) | <0.001 |
| Therapy at index event | |||||||
| Fibrinolysis | 51 (40.8) | 153 (40.0) | 75 (22.8) | 12 (26.7) | 177 (32.0) | 119 (14.0) | <0.001 |
| Primary or urgent PCI | 20 (16.0) | 36 (9.4) | 14 (4.3) | 8 (17.8) | 59 (10.7) | 56 (6.6) | <0.001 |
| In-hospital therapy | |||||||
| Aspirin and/or clopidogrel | 122 (97.6) | 376 (98.4) | 313 (95.1) | 45 (100) | 540 (97.8) | 827 (96.9) | 0.18 |
| Heparins | 124 (99.2) | 374 (97.9) | 309 (93.9) | 44 (97.8) | 542 (98.2) | 811 (95.1) | 0.001 |
| Beta- blockers | 117 (93.6) | 332 (86.9) | 239 (72.6) | 42 (93.3) | 513 (92.9) | 671 (78.7) | <0.001 |
| ACE inhibitors or ARBs | 109 (87.2) | 306 (80.1) | 231 (70.2) | 42 (93.3) | 501 (90.8) | 727 (85.2) | <0.001 |
| CCBs | 12 (9.6) | 9 (2.4) | 12 (3.7) | 3 (6.7) | 40 (7.3) | 77 (9.0) | 0.001 |
| Statins | 117 (93.6) | 332 (86.9) | 259 (78.7) | 41 (91.1) | 522 (94.6) | 763 (89.5) | <0.001 |
| Therapy at discharge | |||||||
| Aspirin and/or clopidogrel | 123 (98.4) | 338 (88.5) | 255 (77.5) | 40 (88.9) | 509 (98.2) | 688 (80.7) | <0.001 |
| ACE inhibitors or ARBs | 102 (81.6) | 289 (875.7) | 219 (66.6) | 40 (88.9) | 471 (85.3) | 653 (76.6) | <0.001 |
| Beta-blockers | 114 (91.2) | 318 (83.3) | 223 (67.8) | 39 (86.7) | 483 (87.5) | 613 (71.79 | <0.001 |
| CCB | 11 (8.8) | 14 (3.7) | 18 (5.5) | 3 (6.7) | 41 (7.4) | 82 (9.69 | 0.01 |
| Statins | 114 (91.2) | 314 (82.2) | 232 (70.5) | 39 (86.7) | 493 (89.3) | 662 (77.6) | <0.001 |
| Diuretics | 6 (4.8) | 41 (10.7) | 76 (23.1) | 5 (11.19 | 141 (25.5) | 285 (33.4) | <0.001 |
| . | Non-hypertensive (n = 836) . | Hypertensive (n = 1450) . | P-value . | ||||
|---|---|---|---|---|---|---|---|
| <45 years (n = 125) . | 45–65 years (n = 382) . | >65 years (n = 329) . | <45 years (n = 45) . | 45–65 years (n = 552) . | >65 years (n = 853) . | ||
| Therapy before admission | |||||||
| Aspirin | 10 (8.0) | 37 (9.7) | 46 (14.0) | 7 (15.6) | 144 (26.1) | 287 (33.7) | <0.001 |
| Clopidogrel | 1 (0.8) | 11 (2.9) | 4 (1.2) | 2 (4.5) | 29 (5.3) | 37 (4.3) | 0.02 |
| Beta-blockers | 5 (4.0) | 45 (11.8) | 46 (14.0) | 11 (24.4) | 172 (31.2) | 299 (35.1) | <0.001 |
| ACE inhibitors | 2 (1.6) | 18 (4.7) | 45 (13.7) | 8 (17.8) | 201 (36.4) | 387 (45.4) | <0.001 |
| ARBs | 2 (1.6) | 2 (0.5) | 3 (0.9) | 3 (6.7) | 16 (2.9) | 37 (4.3) | <0.001 |
| CCB | 3 (2.4) | 11 (2.9) | 11 (3.3) | 1 (2.2) | 48 (8.7) | 132 (14.5) | <0.001 |
| Statins | 7 (5.6) | 35 (9.2) | 31 (9.4) | 9 (20.0) | 118 (21.49) | 189 (22.2) | <0.001 |
| Therapy at index event | |||||||
| Fibrinolysis | 51 (40.8) | 153 (40.0) | 75 (22.8) | 12 (26.7) | 177 (32.0) | 119 (14.0) | <0.001 |
| Primary or urgent PCI | 20 (16.0) | 36 (9.4) | 14 (4.3) | 8 (17.8) | 59 (10.7) | 56 (6.6) | <0.001 |
| In-hospital therapy | |||||||
| Aspirin and/or clopidogrel | 122 (97.6) | 376 (98.4) | 313 (95.1) | 45 (100) | 540 (97.8) | 827 (96.9) | 0.18 |
| Heparins | 124 (99.2) | 374 (97.9) | 309 (93.9) | 44 (97.8) | 542 (98.2) | 811 (95.1) | 0.001 |
| Beta- blockers | 117 (93.6) | 332 (86.9) | 239 (72.6) | 42 (93.3) | 513 (92.9) | 671 (78.7) | <0.001 |
| ACE inhibitors or ARBs | 109 (87.2) | 306 (80.1) | 231 (70.2) | 42 (93.3) | 501 (90.8) | 727 (85.2) | <0.001 |
| CCBs | 12 (9.6) | 9 (2.4) | 12 (3.7) | 3 (6.7) | 40 (7.3) | 77 (9.0) | 0.001 |
| Statins | 117 (93.6) | 332 (86.9) | 259 (78.7) | 41 (91.1) | 522 (94.6) | 763 (89.5) | <0.001 |
| Therapy at discharge | |||||||
| Aspirin and/or clopidogrel | 123 (98.4) | 338 (88.5) | 255 (77.5) | 40 (88.9) | 509 (98.2) | 688 (80.7) | <0.001 |
| ACE inhibitors or ARBs | 102 (81.6) | 289 (875.7) | 219 (66.6) | 40 (88.9) | 471 (85.3) | 653 (76.6) | <0.001 |
| Beta-blockers | 114 (91.2) | 318 (83.3) | 223 (67.8) | 39 (86.7) | 483 (87.5) | 613 (71.79 | <0.001 |
| CCB | 11 (8.8) | 14 (3.7) | 18 (5.5) | 3 (6.7) | 41 (7.4) | 82 (9.69 | 0.01 |
| Statins | 114 (91.2) | 314 (82.2) | 232 (70.5) | 39 (86.7) | 493 (89.3) | 662 (77.6) | <0.001 |
| Diuretics | 6 (4.8) | 41 (10.7) | 76 (23.1) | 5 (11.19 | 141 (25.5) | 285 (33.4) | <0.001 |
Values are expressed as numbers, n (%) or mean ± SD.
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptors blockers; CCBs, calcium-channel blockers.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
